Plain-English translation of NCT06525428 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for advanced colorectal cancer that doesn't respond to standard immunotherapy. Researchers are combining toripalimab—an immunotherapy drug that helps your immune system fight cancer—with standard chemotherapy and focused radiation therapy. The goal is to see if this three-part treatment works better than chemotherapy alone.
Many people with advanced colon cancer have tumors that don't respond to current immunotherapy options. Researchers hope that combining this medication with radiation and chemotherapy might help more patients benefit from immunotherapy and control their cancer better.
You likely qualify if…
You likely don't qualify if…
You will receive standard chemotherapy on a regular schedule, along with the new immunotherapy medication toripalimab every three weeks. You'll also receive focused radiation therapy (either a few high-dose treatments or several lower-dose treatments, depending on your tumor) to at least one area of cancer. Your doctors will monitor your response with scans and blood tests throughout treatment and follow your health afterward.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China